vs
Side-by-side financial comparison of Astria Therapeutics, Inc. (ATXS) and NUSATRIP Inc (NUTR). Click either name above to swap in a different company.
NUSATRIP Inc is the larger business by last-quarter revenue ($768.7K vs $706.0K, roughly 1.1× Astria Therapeutics, Inc.). NUSATRIP Inc runs the higher net margin — -125.4% vs -4482.0%, a 4356.6% gap on every dollar of revenue.
Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for rare hematological and allergic diseases with high unmet medical needs. Its core pipeline includes drug candidates designed to address life-threatening immune-mediated conditions, serving patient populations across North America and other global markets with limited existing treatment options.
NUSATRIP Inc is a travel technology company that operates a full-service online travel booking platform primarily catering to Southeast Asian markets. It provides flight ticketing, hotel accommodation reservations, customized holiday packages, and local experience bookings for both leisure travelers and small business travel clients.
ATXS vs NUTR — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $706.0K | $768.7K |
| Net Profit | $-31.6M | $-963.7K |
| Gross Margin | — | 100.0% |
| Operating Margin | -4830.6% | -162.3% |
| Net Margin | -4482.0% | -125.4% |
| Revenue YoY | — | — |
| Net Profit YoY | -29.0% | — |
| EPS (diluted) | $-0.55 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $706.0K | $768.7K | ||
| Q2 25 | — | $993.0K | ||
| Q3 24 | $0 | — |
| Q3 25 | $-31.6M | $-963.7K | ||
| Q2 25 | — | $920.3K | ||
| Q3 24 | $-24.5M | — |
| Q3 25 | — | 100.0% | ||
| Q2 25 | — | 100.0% | ||
| Q3 24 | — | — |
| Q3 25 | -4830.6% | -162.3% | ||
| Q2 25 | — | 41.2% | ||
| Q3 24 | — | — |
| Q3 25 | -4482.0% | -125.4% | ||
| Q2 25 | — | 92.7% | ||
| Q3 24 | — | — |
| Q3 25 | $-0.55 | $-0.17 | ||
| Q2 25 | — | $0.25 | ||
| Q3 24 | $-0.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $227.7M | $5.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $233.3M | $12.5M |
| Total Assets | $271.9M | $27.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $227.7M | $5.1M | ||
| Q2 25 | — | $6.9M | ||
| Q3 24 | $344.3M | — |
| Q3 25 | $233.3M | $12.5M | ||
| Q2 25 | — | $-1.9M | ||
| Q3 24 | $341.7M | — |
| Q3 25 | $271.9M | $27.0M | ||
| Q2 25 | — | $19.3M | ||
| Q3 24 | $361.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-32.3M | $-17.0M |
| Free Cash FlowOCF − Capex | — | $-17.0M |
| FCF MarginFCF / Revenue | — | -2207.9% |
| Capex IntensityCapex / Revenue | 0.0% | 0.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-32.3M | $-17.0M | ||
| Q2 25 | — | $-1.5M | ||
| Q3 24 | $-28.0M | — |
| Q3 25 | — | $-17.0M | ||
| Q2 25 | — | $-1.5M | ||
| Q3 24 | $-28.0M | — |
| Q3 25 | — | -2207.9% | ||
| Q2 25 | — | -152.2% | ||
| Q3 24 | — | — |
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | — | 0.5% | ||
| Q3 24 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | -1.64× | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
